Core Viewpoint - Tianchen Medical (688013.SH) has significantly raised its share repurchase price limit from a maximum of 28.03 CNY per share to 70.00 CNY per share, reflecting a strong market performance and strategic adjustments in its repurchase plan [1]. Group 1: Share Repurchase Plan - The initial share repurchase plan was announced on December 27, 2023, with a total repurchase fund of no less than 18 million CNY and no more than 36 million CNY, at a price not exceeding 30 CNY per share [1]. - On July 9, 2024, the company announced an increase in the repurchase amount, adjusting the total repurchase fund to no less than 36 million CNY and no more than 72 million CNY [1]. - As of now, Tianchen Medical has repurchased a total of 2.5053 million shares, accounting for 3.09% of the total share capital, with a total payment of approximately 42.499 million CNY [2]. Group 2: Financial Performance - Tianchen Medical's total assets were 676 million CNY as of September 2025, indicating a relatively small asset scale [3]. - From 2021 to 2024, the company's operating revenue increased from 214 million CNY to 272 million CNY, while net profit attributable to shareholders rose from approximately 41.42 million CNY to 51.89 million CNY [3]. - In the first three quarters of 2025, the company achieved operating revenue of 244 million CNY, a year-on-year increase of 20.66%, and net profit of 71.95 million CNY, a year-on-year increase of 68.29% [3].
天臣医疗股价年内涨2倍上调回购价 产品放量成本优化前三季净利增68%